Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn MorePituitary tumors, also known as pituitary neoplasms, are abnormal growths that develop in the pituitary gland, a small yet crucial endocrine gland located at the base of the brain. Alfa Cytology is committed to pioneering new therapeutic approaches for pituitary tumors treatment for our clients.
The pituitary gland is a pea-sized endocrine gland located at the base of the brain. The pituitary gland regulates and controls the secretion of hormones from other endocrine glands, which in turn regulate many bodily processes. These hormones include growth hormone (GH), thyroid stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), and prolactin.
Fig.1 Standardized incidence rate of primary pituitary adenoma. (Chen C., et al., 2021)
The cause of pituitary tumors is not known and most pituitary tumors are located in the anterior pituitary gland and are usually benign (non-cancerous). About 75% of pituitary tumors secrete hormones. When the tumor produces excessive amounts of one or more hormones, gigantism or acromegaly, hyperthyroidism, Cushing's syndrome, and prolactinoma may occur. As pituitary tumors grow, some hormone-secreting cells of the pituitary gland may be destroyed, leading to symptoms associated with inadequate production of the suppressed hormone (hypopituitarism).
Very rare pituitary cancers are characterized by the presence of craniospinal and/or systemic metastases. Despite previous surgery and radiation therapy, a large percentage of invasive pituitary tumors continue to progress and therefore require additional treatment options. Recent advancements have focused on non-surgical interventions, particularly targeted therapies.
NCT | Target | Therapeutics | Phase |
NCT02749227 | Second-generation Somatostatin Receptor Ligand | Pasireotide LAR | |
NCT04042753 | PD L1 Inhibitor | Lpilimumab and Nivolumab | |
NCT02288962 | Dopamine Agonist | Cabergoline |
At Alfa Cytology, we specialize in preclinical services tailored to the unique needs of clients working in the field of pituitary tumors and other oncological research. Our offerings include:
Therapeutics Development
For more information about our services related to pituitary tumors or to discuss potential research collaborations, please reach out to Alfa Cytology. Our dedicated team is ready to assist you in navigating the complexities of pituitary tumor research.
Reference